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Abstract
Trisomy 13 (T13) and trisomy 18 (T18) are among the most prevalent autosomal trisomies. Both 
are associated with a very high risk of mortality. Numerous instances, however, of long-term 
survival of children with T13 or T18 have prompted some clinicians to pursue aggressive 
treatment instead of the traditional approach of palliative care. The purpose of this study is to 
assess current mortality data for these conditions. This multi-state, population-based study 
examined data obtained from birth defect surveillance programs in nine states on live-born infants 
delivered during 1999–2007 with T13 or T18. Information on children’s vital status and selected 
maternal and infant risk factors were obtained using matched birth and death certificates and other 
data sources. The Kaplan–Meier method and Cox proportional hazards models were used to 
estimate age-specific survival probabilities and predictors of survival up to age five. There were 
693 children with T13 and 1,113 children with T18 identified from the participating states. Among 
children with T13, 5-year survival was 9.7%; among children with T18, it was 12.3%. For both 
trisomies, gestational age was the strongest predictor of mortality. Females and children of non-
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Hispanic black mothers had the lowest mortality. Omphalocele and congenital heart defects were 
associated with an increased risk of death for children with T18 but not T13. This study found 
survival among children with T13 and T18 to be somewhat higher than those previously reported 
in the literature, consistent with recent studies reporting improved survival following more 
aggressive medical intervention for these children.
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INTRODUCTION
Next to Down syndrome, trisomy 13 (T13) and trisomy 18 (T18) are the most common 
autosomal trisomies diagnosed in fetuses and infants. The prevalence of T13 among live 
born infants in the United States (US) is approximately 0.81 per 10,000, or about 1 in 12,340 
live births, and for T18 the birth prevalence is 1.5 per 10,000, or about 1 in 6,670 live births 
[Parker et al., 2010]. Inclusion of fetal deaths and pregnancy terminations in these numbers 
increases the estimated prevalence by about 2.5- to fourfold [Crider et al., 2008; Parker et 
al., 2010]. Among pregnancies that are prenatally diagnosed with T13 only 18.9% have been 
reported to result in a live birth and, for T18, 13.5% are live-born [Tonks et al., 2013]. The 
majority of prenatally diagnosed pregnancies are electively terminated [Irving et al., 2011; 
Tonks et al., 2013]. Affected infants usually have major congenital malformations, including 
congenital heart defects (CHDs) such as septal defects and aortic and pulmonary valve 
anomalies, orofacial clefts, omphalocele, renal anomalies, and central nervous system 
malformations [Jones et al., 2013].
Children born with T13 and T18 have a poor prognosis, with a very high rate of infant 
mortality [Rasmussen et al., 2003; Vendola et al., 2010; Lakovschek et al., 2011]. Median 
survival times of 7–10 days for T13 and 10–14.5 days for T18 were reported by Rasmussen 
et al. [2003]
 and are consistent with other studies [Lakovschek et al., 2011]. Despite the poor 
prognosis for these infants, several case reports have been published describing instances of 
long-term survival of children with T13 and T18, occasionally into the second decade of life 
[Redheendran et al., 1981; Tunca et al., 2001; Peroos et al., 2012]. In addition, many 
families of longer term survivors share information on their child’s progress in 
developmental areas, such as language and communication and motor skills, with 
researchers and support groups such as the Support Organization for Trisomy 18, 13, and 
Related Disorders [Baty et al., 1994; Bruns, 2015; SOFT, 2015]. These reports have 
prompted some clinicians to pursue a more aggressive strategy in managing affected infants, 
instead of opting for the traditional approach of providing mainly palliative care. A recent 
analysis of hospital utilization among infants and children with T13 and T18 in the United 
States seems to support this trend of more aggressive medical management [Nelson et al., 
2012]. That study found an increasing number of in-patient hospital stays over time (for 
T18) and numerous therapeutic procedures being performed on the children, many of whom 
were over 1 year of age.
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In recent years, there has been debate regarding the extent to which technological 
interventions should be employed in the management of infants with these trisomies 
[Kaneko et al., 2008; Janvier et al., 2011; Carey, 2012; Merritt et al., 2012]. In order for 
caregivers and parents to make informed decisions about caring for a child with T13 or T18, 
accurate and current information regarding infant and childhood survival, including factors 
influencing survival, is critical. In this study, we estimated survival, and quantified important 
predictors of survival, using a large, population-based sample of infants born with T13 and 
T18 from a multi-state collaboration of US birth defect surveillance systems.
MATERIALS AND METHODS
Data Sources
The data for this study were collected as a part of a larger collaborative study of survival 
among children with selected major birth defects ascertained from 12 state-based birth 
defect surveillance programs [Wang et al., 2015]. For the present study, we restricted the 
analysis to nine states that used either active case ascertainment or passive case 
ascertainment with medical record confirmation of the diagnoses. The participating states in 
this study, and the inclusive birth cohorts used, are Arizona (1999–2007), Colorado (1999–
2006), Georgia (5-county metropolitan Atlanta area) (1999–2007), Illinois (2002–2006), 
Massachusetts (2000–2007), New Jersey (1999–2005), New York (1999–2007), North 
Carolina (2003–2007), and Texas (1999–2007). The present study includes all live-born 
infants diagnosed with T13 or T18, who were residents of one of the participating nine states 
and were delivered in the years specified above. States using active ascertainment methods 
to identify cases were Arizona, Georgia, Massachusetts, North Carolina, and Texas; the 
remaining four states used passive surveillance with follow-up review of the medical record 
to verify the diagnosis. States were asked to exclude suspected or possible cases of T13 and 
T18 but, due to local differences in coding and abstraction procedures, we were not able to 
distinguish between full trisomies, partial or Robertsonian trisomies, and mosaics in most 
states. Thus, our study sample consisted of all T13 and T18 cytogenetic variants.
Each of the participating states matched their infants born with T13 or T18 to their 
respective birth certificate records to obtain demographic information and other maternal 
and infant characteristics that could be associated with survival. Variables included in this 
analysis were child’s sex (male, female), clinical estimate of gestational age (<32 weeks; 
32–36 weeks, ≥37 weeks), plurality (single, multiple), period of birth (1999–2002, 2003–
2007), and maternal characteristics, including age (≤19, 20–24, 25–29, 30–34, ≥35 years), 
race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, non-Hispanic Asian/
Pacific Islander, non-Hispanic other), state of residence, and population density of maternal 
county of residence at delivery (metropolitan, nonmetropolitan), based on 2003 Rural–Urban 
Continuum codes [USDA, 2013].
Because infants with T13 and T18 often present with a wide spectrum of other serious birth 
defects that could alter the course of treatment or survival, we also collected data on selected 
co-occurring major congenital malformations, which were ascertained by the surveillance 
program and reported for each infant. We focused on those malformations that are most 
commonly reported among these infants, and most likely to influence survival. These 
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include omphalocele and selected major CHDs (common truncus, transposition of great 
arteries, tetralogy of Fallot, atrio-ventricular septal defect, aortic valve stenosis, hypoplastic 
left heart syndrome, and coarctation of aorta). Although other CHDs, such as patent ductus 
arteriosus, atrial septal defects, and ventricular septal defects, are quite common in children 
with T13 and T18, they are not typically associated with an increased risk of mortality; thus, 
we chose to limit our analysis to the rarer but more severe CHD phenotypes listed above.
To determine the vital status of each child, participating surveillance programs linked their 
infants born with T13 or T18 to their state death certificate files. To augment the state vital 
statistics data, Arizona and Texas also used medical records data, and Georgia used National 
Death Index (NDI) data. For decedent children, participating states provided the month and 
year of death and age at death (in days). Vital status was ascertained through December 31, 
2008; thus the length of the follow-up period varied depending on the birth cohort. If there 
was no documentation of the child’s death, the child was assumed to be alive for the 
duration of follow-up, consistent with the approach used by Wang et al. [2015]. One state 
(Illinois) provided mortality data only up to 1 year of age, and was, therefore, excluded from 
analyses of survival beyond the first year of life. Each surveillance program removed all 
personal identifiers from their data and sent a deidentified dataset to the Centers for Disease 
Control and Prevention (CDC) for consolidation, formatting, and data cleaning prior to 
analysis.
Statistical Analysis
We used the Kaplan–Meier (K–M) product limit method to estimate unconditional and 
conditional age-specific survival probabilities (<1 day, <7 days, <28 days, <1 year, <5 years) 
separately for children with T13 and T18 [Lee, 1980]. Unconditional survival probabilities 
provided estimates of the likelihood of survival at each age interval measured from the time 
of birth, whereas conditional survival probabilities estimated the likelihood of survival at a 
specified age interval given the individual has survived to the preceding interval. We used 
Greenwood’s method to calculate 95% confidence intervals (CI) for the survival probability 
estimates [Kalbfleisch and Prentice, 2002]. Using the K–M method and the log-rank test, we 
performed bivariate analyses and generated survival curves to identify maternal and infant 
risk factors associated with survival. To identify a set of predictive factors associated with 
survival, we selected those risk factors that had a P-value of <0.20 in the bivariate analyses 
and included them in a multivariable analysis using the Cox proportional hazards model 
[Cox, 1972]. Separate models were run for T13 and T18 to examine survival at ages 1 and 5. 
Adjusted hazard ratios (aHR) and 95% CIs generated from the Cox models provided risk 
estimates for each of the explanatory variables while simultaneously controlling for all other 
variables in the model. We used SAS Version 9.2 to conduct all statistical analyses for this 
study (SAS Institute, Cary, NC).
RESULTS
There were a total of 693 children with T13 and 1,113 children with T18 identified from the 
nine states (Table I). Texas contributed the largest percentage of subjects to this study (about 
37%). More than one-half of the children were born in the latter time period (2003–2007), 
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which was due to the increased number of states providing data during the latter years. 
Almost 90% of the children were from metropolitan areas. Children with T13 were evenly 
split by gender, but a substantially higher proportion of the children with T18 were female 
(61.2%) compared to male (38.4%). As expected, the maternal age distribution among the 
infants was skewed toward the older age categories. This was most notable for T18, in which 
almost 46% of the mothers were 35 years or older. The distribution of maternal race/
ethnicity was similar for both phenotypes. About 17% of the children had one or more of the 
CHDs listed above. Omphalocele was diagnosed in 7.5% of the infants with T13 and 5.2% 
of the infants with T18.
Median survival for children with T13 and T18 was 5 and 8 days, respectively. Although 
mortality was quite high for both phenotypes, some differences were evident across the 5-
year time span (Table II). Children with T13 had poorer survival than children with T18 at 
each time point examined, most notably at 7 and 28 days. Survival for infants with T13 fell 
from 74.6% after the first day of life to 25.5% at 28 days. For infants with T18, survival 
declined from 78.1% after the first day to 37.2% at 28 days. Among the children with T13, 
9.7% survived to age 5, whereas 5-year survival for children with T18 was 12.3%.
Although the cumulative probability of survival for both T13 and T18 decreased 
precipitously throughout infancy, conditional survival probabilities showed a less marked 
decline after the first day of life (Table III). Among infants with T13, those who survived the 
first day of life had approximately a 58% chance of surviving to seven days, and those who 
lived to seven days had about the same chance of surviving to 28 days. Infants with T18 who 
survived the first week had about a 71% chance of surviving through the neonatal period. 
Children with either condition who survived the first year of life had better than an 80% 
chance of surviving to age 5.
Table IV shows 1-month and 1-year survival probabilities for infants with T13 by selected 
maternal and infant risk factors. For most factors examined there were no statistically 
significant differences in survival, including maternal age, presence of selected major CHDs 
or omphalocele, and birth period. Female infants had significantly higher survival 
probabilities than males at both 1 month and 1 year of age. Infants born full term (≥37 weeks 
gestation) had substantially better survival compared to their counterparts born either 
moderately preterm (32–36 weeks) or very preterm (<32 weeks). Infants of non-Hispanic 
black mothers had the highest survival probability at 1 month, whereas Hispanic infants had 
the lowest survival at both 1 month and 1 year of age. Infants whose mothers resided in a 
metropolitan area at the time of delivery had a higher probability of survival than those from 
non-metropolitan areas, particularly at 1 year. Although the differences were not statistically 
significant, we also found differences in survival by state of residence. The lowest 1-month 
survival probabilities were among infants from Arizona and Illinois. One-year survival was 
lowest for Arizona and North Carolina. Infants from Georgia and New Jersey had the 
highest survival at both 1 month and 1 year.
Kaplan–Meier survival curves displaying differences in 1-year survival by sex, gestational 
age, maternal race/ethnicity, maternal residence (metropolitan/non-metropolitan), presence 
of CHDs, and presence of omphalocele for infants with T13 are presented in Figure 1. 
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Survival was consistently better for females, full term infants and for infants from 
metropolitan areas at each time point throughout the first year of life. The trend in survival 
patterns by race/ethnicity during the first year was not as clear, and the differences were not 
statistically significant. Children with CHDs or omphalocele had slightly lower survival 
compared to those without these anomalies, but the differences were not statistically 
significant.
The 1-month and 1-year survival probabilities for infants with T18 by selected maternal and 
infant risk factors are shown in Table V. Similar to the pattern seen for T13, among infants 
with T18, survival was highest for females, full term infants and for infants whose mothers 
resided in a metropolitan area. Survival was also higher for singleton infants compared to 
multiples. Infants born to non-Hispanic black mothers, and infants of other/ unknown race, 
had the highest survival probabilities at both 1 month and 1 year. Differences in survival by 
state were also apparent, with Arizona and Illinois infants having the lowest 1-month 
survival, and Arizona and North Carolina having the lowest survival at age 1. Georgia and 
Massachusetts had the highest survival probabilities at both 1 month and 1 year. Infants with 
trisomy 18 and omphalocele had lower survival than their counterparts without omphalocele. 
Infants with major CHDs had a lower probability of survival at one year of age compared to 
those infants without, although the difference was not statistically significant. Similar to 
T13, for children with T18 there were no differences in survival by birth period or maternal 
age.
Figure 2 presents 1-year survival curves for infants with T18 by selected risk factors. 
Significantly higher survival throughout the first year of life is evident for females, full term 
infants, and infants from metropolitan areas. Likewise, higher survival for infants of non-
Hispanic black mothers is apparent during the first year. Children with T18 and who had 
major CHDs or omphalocele had worse survival compared to their counterparts without 
these malformations. This difference was most apparent for omphalocele.
Table VI presents adjusted hazard ratios for mortality at 1 and 5 years of age for selected 
risk factors for children with T13 and T18. Controlling for all other risk factors in the model, 
being born preterm, particularly <32 weeks, was associated with the highest hazard ratios at 
both 1 and 5 years. This was true for both T13 and T18, although the association was 
stronger among the latter. For children with T18, being diagnosed with omphalocele and, to 
a lesser extent, CHDs, was associated with an increased mortality risk at age 1 and 5. For 
both T13 and T18, hazard ratios were less than unity for females, with a slightly stronger 
association for T18. Children of non-Hispanic black mothers had a lower mortality risk 
compared to non-Hispanic whites for both phenotypes. After controlling for other risk 
factors, there were also some survival differences by state. Compared to the referent state 
(Texas), residents of Arizona and Massachusetts had elevated aHRs for T13 at age 5, 
whereas for T18, New York residents had a lower hazard ratio at both ages. Georgia 
residents had a lower hazard ratio for both T13 and T18 at age 1, although these differences 
were not statistically significant.
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DISCUSSION
This is the largest population-based study of survival among children with T13 or T18 
published to date, and the first study with sufficient statistical power to characterize an array 
of maternal and infant factors potentially related to survival. After adjusting for other 
explanatory factors, we found that children with T13 and T18 who were born very preterm 
(<32 weeks gestation) had at least a two fold increased risk of mortality compared to their 
counterparts born at term. Gestational age was the strongest independent determinant of 
survival in our study, which is noteworthy because about one-half of the children with T13 
and T18 were born preterm. Children with either condition who were born very preterm had 
the poorest survival, but those born between 32 and 36 weeks also had increased mortality 
compared to term infants. At least two other studies found a survival differential among 
children with T18 by gestational age [Niedrist et al., 2006; Wu et al., 2013]. Both of these 
studies found that infants born ≥37 weeks gestation had better survival compared to infants 
born at earlier gestational ages. To our knowledge, the current study is the first with 
sufficient statistical power to demonstrate that gestational age is an important predictor of 
survival in both T13 and T18, independent of other factors such as gender, race/ethnicity and 
state of residence. In a recent multicenter study comparing outcomes among a cohort of very 
low birth weight (VLBW) infants with T13, T18, Down syndrome, and infants without 
major birth defects, Boghossian et al. [2014] found that mortality was substantially higher 
among infants with T13 and T18 compared to the other two groups. However, that study was 
limited to infants born VLBW who were treated at neonatal intensive care units, and did not 
include a referent group of normal weight infants for comparison. It is possible that the high 
mortality among infants with T13 or T18 and who are VLBW may be due, in part, to a 
tendency to withhold aggressive neonatal care which would typically be provided to other 
very preterm infants [Boghossian et al., 2014].
Although the median survival of children with T13 (5 days) and T18 (8 days) in our study 
was comparable to previously reported findings, survival rates at 1 year of age were higher 
than those reported in some other recent studies, which ranged from about 3% to 8% 
[Rasmussen et al., 2003; Vendola et al., 2010; Irving et al., 2011]. There are several possible 
explanations for this. First, our study population included infants with various expressions of 
T13 and T18, including cytogenetic mosaics and Robertsonian translocations. Greatly 
improved long-term survival has been observed for children with partial or mosaic trisomies 
compared to children with full trisomy. For example, Wu et al. [2013] reported 1-year 
survival rates of 29% and 70% for children with partial T13 and partial T18, respectively. 
Although the proportion of such cytogenetic variations relative to full trisomy 13 or 18 is 
relatively small [Parker et al., 2003; Wu et al., 2013], it is likely that inclusion of these 
variants in our study population had at least some impact on the observed survival rates. 
Another possible explanation for the relatively higher survival in our study compared to 
earlier reports could be increased prenatal detection and termination of trisomy fetuses with 
major malformations or pregnancy complications such as holoprosencephaly, complex 
congenital heart defects, oligohydramnios or severe fetal growth restriction. Selective 
termination of fetuses with the poorest prognosis could result in a higher proportion of less 
severely affected fetuses with T13 and T18 being born alive, thus increasing median and 
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overall survival rates. Our study found a slightly lower prevalence of major CHDs and 
omphalocele compared to some other studies, which is consistent with such an explanation.
Similar to previously published reports, our study found very high mortality within the first 
week of life. For infants who survived the first week, however, the survival outlook 
improved. Infants with T13 who survived the first week had nearly a 60% chance of 
neonatal survival, and children with trisomy 18 who survived the first week had better than a 
70% chance. Children with either phenotype who survived the first year had a very good 
chance of living to age 5. These findings, although seemingly encouraging and potentially 
useful for patient counseling, should be interpreted with caution because overall prolonged 
survival in T13 and T18 remains rare, and is likely to be largely dependent on genotypic 
variation and the child’s associated medical complications. For example, in an analysis of 
conditional survival of infants with full T13 or T18, Brewer et al. [2002] found improving 
chances of survival only up to 1 month of age. For infants who survived one month, survival 
to 1 year was only about 10% in both groups.
Our study found that infants with T18 and omphalocele had a 50% increased risk of 
mortality at 1 and 5 years compared to those without an omphalocele, after adjusting for 
other risk factors. Omphalocele was not associated with survival among children with T13. 
About 5% of the children with T18 in our study had an omphalocele, compared to 14.3% 
from a Swiss population [Niedrist et al., 2006], 7–9% as found by Baty et al. [1994] from a 
sample of families participating in a national support group, 5% from a hospital-based 
sample in Taipei [Lin et al., 2006] and <1% as reported in analysis of the national Healthcare 
Cost and Utilization project (HCUP) [Pont et al., 2006].
Among children with T13, presence of selected major CHDs showed no substantial effect on 
either 1-month or 1-year survival. For children with T18, the presence of CHD was 
associated with an increased risk of death at both 1 and 5 years of age. These findings 
contrast with those of some previous studies that found no survival differences between 
affected children with and without CHDs, although those studies included CHD subtypes 
that were not captured in our study, and presented with a wider range of severity, such as 
ventricular septal defects [Rasmussen et al., 2003; Niedrist et al., 2006; Wu et al., 2013].
As reported in several previous studies [Weber, 1967; Baty et al., 1994; Rasmussen et al., 
2003; Lin et al., 2006; Niedrist et al., 2006], we found a survival advantage for female 
children relative to males for both T13 and T18. After controlling for potential confounders, 
this association held for T18 but was not as strong for children with T13. The reasons for the 
higher survival among females are unclear, but this finding is generally consistent across the 
majority of previous studies. Additionally, as our study shows, the gender difference persists 
even after controlling for factors such as gestational age and occurrence of co-morbidities 
such as omphalocele and CHDs.
We found survival to be slightly higher among children of non-Hispanic black mothers 
compared to non-Hispanic whites after adjusting for other variables, but no other racial/
ethnic differences of note were evident. This finding is consistent with that of Rasmussen et 
al. [2003]
, which used data from the metropolitan Atlanta area. On the other hand, Vendola 
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et al. [2010] found no association between race/ethnicity and survival in a cohort from 
Texas. The findings of higher survival among females and among children of non-Hispanic 
black mothers warrant further investigation.
After controlling for other risk factors, our study also found some survival differences 
among the nine states. It is possible that local differences in the aggressiveness of medical 
management of infants with T13 or T18 may contribute to the variation in survival among 
states. Some studies suggest that cardiac surgery and more intensive neonatal treatment may 
prolong survival of some infants with T13 and T18 [Kosho, 2006; Kaneko et al., 2008, 2009; 
Maeda et al., 2011; Tsukada et al., 2012]. There continues to be much discussion and varied 
opinion within the medical community about when to use more aggressive treatment 
options, and how much care is “the right amount” given the poor prognosis of children with 
these disorders [Carey, 2012]. Treatment practices for these patients do vary among hospitals 
and physicians, but whether differences in medical care contributed to the observed 
differences in survival between the states in this study is unclear. Furthermore, as noted by 
Hsu and Hou [2007], other studies have found that many children with T13 have 
experienced prolonged survival without receiving more aggressive care, and suggest that 
variability in the clinical spectrum of T13 is an important determinant in long-term survival.
It is also possible that the observed state-specific differences in survival may be due, at least 
in part, to differences in completeness of ascertaining vital status. The specific data linkage 
methods used to match case information with state death certificates varied by state, and this 
might have led to differences in completeness of ascertainment. Additionally, some of the 
states used other data sources to supplement state mortality files for ascertaining vital status, 
including hospital records and NDI searches; however, there did not appear to be a clear 
pattern associated with the search methods used and survival among the states. Finally, as 
discussed above, it is also possible that differences in prenatal detection and termination 
rates exist among the nine states, which could result in state differences in childhood 
survival.
This study had several strengths. The large sample size enabled us to investigate several 
maternal and infant risk factors potentially related to survival that have not been previously 
studied, such as maternal age, state of residence and gestational age (identified as a new 
predictor of mortality among infants with T13). The study population also comprises a 
national sample of a geographically and racial/ethnically diverse population that was 
obtained from well-established state-based birth defect surveillance systems throughout the 
United States. This allowed us to examine regional and urban/rural differences in survival, 
which previous studies have not been able to address. Also, in our study, diagnoses were 
verified by medical record review in all of the participating states, which included karyotype 
confirmation or other cytogenetic findings when available in the record, in addition to 
clinical exams and other medical documentation supporting the diagnosis. According to data 
available from five of the states, approximately 80% of the children’s medical charts 
contained a karyotype report. We found no significant difference in survival among those 
children whose record did or did not include karyotype confirmation (data not shown).
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This study was subject to some limitations. The lack of specificity in the birth defect coding 
systems used and differences in local case abstraction procedures precluded us from 
distinguishing between full trisomy and partial or mosaic variants. As noted above, although 
the proportion of children with partial or mosaic trisomies is expected to be small, our study 
population was clinically heterogeneous compared with study populations with detailed 
cytogenetic results on all participants. Although this may have contributed to somewhat 
higher long-term survival estimates in our study, it does not appear to have caused 
substantial bias with regard to identification of risk factors associated with survival, as our 
findings with respect to risk factors such as gender and gestational age are largely consistent 
with earlier reports. Also, as previously noted, there was potential for underascertainment of 
deaths in this study, due to children moving out of state during the follow up period, or 
missed matches between the child’s birth and death records. This may have resulted in our 
study overstating the true survival rates, particularly after infancy. However, the one site in 
our study that used NDI to identify deaths (Georgia) had the same or higher survival rates as 
those states that employed state death certificates alone. Another limitation of our study is 
the lack of information on the clinical care provided to the children, preventing us from 
examining the extent to which factors such as cardiac surgery or other therapies may have 
affected survival. This is a critical gap in our current knowledge that could be addressed in 
several ways—with administrative cohorts developed through longitudinal linkages of large 
population-based data sources, or with multicenter hospital-based cohort studies that focus 
on health services utilization and long-term survival.
This multi-state population-based study provides new and updated information on the 5-year 
survival of children born with T13 or T18, including factors that influence survival. Our 
findings support the emerging view that, despite their severity and high mortality, these 
conditions should no longer be routinely regarded as uniformly lethal malformations. This 
information can be helpful to clinicians, parents and other caregivers involved in the 
treatment and decision-making around the care and well-being of children born with T13 or 
T18.
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FIG. 1. 
Kaplan–Meier 1-year survival curves for infants with trisomy 13 by selected risk factors in 
nine US states, 1999–2007 birth cohort.
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FIG. 2. 
Kaplan–Meier 1 year survival curves for infants with trisomy 18 by selected risk factors in 
nine US states, 1999–2007 birth cohort.
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TABLE I
Characteristics of Live Born Infants With Trisomy 13 and Trisomy 18 in Nine US States, 1999–2007 Birth 
Cohort
Characteristic
Trisomy 13 Trisomy 18
Number births Percent Number births Percent
Infant sex
 Male 347 50.1 427 38.4
 Female 340 49.1 681 61.2
 Unknown 6 0.9 5 0.4
Gestational age
 <32 weeks 122 17.6 206 18.5
 32–36 weeks 223 32.2 277 24.9
 ≥37 weeks 336 48.5 605 54.4
 Unknown 12 1.7 25 2.2
Plurality
 Single 675 97.4 1,065 95.7
 Multiple 15 2.2 41 3.7
 Unknown 3 0.4 7 0.6
Maternal race/ethnicity
 Non-Hispanic White 327 47.2 471 42.3
 Non-Hispanic Black 110 15.9 208 18.7
 Hispanic 217 31.3 366 32.9
 Non-Hispanic Asian/PI 21 3.0 38 3.4
 Other/unknown 18 2.6 30 2.7
Maternal age
 <19 years 53 7.6 67 6.0
 20–24 years 126 18.2 156 14.0
 25–29 years 149 21.5 179 16.1
 30–34 years 155 22.4 200 18.0
 ≥35 years 210 30.3 511 45.9
Geographic area
 Metropolitan 618 89.2 991 89.0
 Non-metropolitan 72 10.4 117 10.5
 Unknown 3 0.4 5 0.4
State
 Arizona 68 9.8 118 10.6
 Colorado 52 7.5 59 5.3
 Georgia 32 4.6 61 5.5
 Illinois 63 9.1 127 11.4
 Massachusetts 37 5.3 49 4.4
 North Carolina 50 7.2 92 8.3
 New Jersey 50 7.2 76 6.8
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Characteristic
Trisomy 13 Trisomy 18
Number births Percent Number births Percent
 New York 85 12.3 127 11.4
 Texas 256 36.9 404 36.3
Presence of heart defectsa
 With heart defects 117 16.9 193 17.3
 No heart defects 576 83.1 920 82.7
Presence of omphalocele
 With omphalocele 52 7.5 58 5.2
 No omphalocele 641 92.5 1,055 94.8
Birth period
 1999–2002 264 38.1 400 35.9
 2003–2007 429 61.9 713 64.1
Total 693 100.0 1,113 100.0
a
Heart defects include common truncus, transposition of great arteries, tetralogy of Fallot, atrioventricular septal defect, aortic valve stenosis, 
hypoplastic left heart syndrome, and coarctation of aorta.
PI, Pacific Islander.
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TABLE IV
One-Month and 1-Year Survival Probabilities (Expressed as Percentage) for Trisomy 13 in Nine US States, 
1999–2007 Birth Cohort
Characteristica
1-month survival probability 
(95%CI)
P-valueb for 
difference in 1-
month survival
1-year survival probability 
(95%CI)
P-valueb for 
difference in 1-
year survival
Infant sex
 Male 18.7 (14.8, 23.0) 0.001 8.9 (6.2, 12.2) 0.003
 Female 28.8 (24.1, 33.7) 13.5 (10.1, 17.4)
Gestational age
 <32 weeks 9.0 (4.8, 14.9) <0.001 6.6 (3.1, 11.9) <0.001
 32–36 weeks 19.7 (14.8, 25.2) 8.1 (5.0, 12.1)
 ≥37 weeks 31.2 (26.4, 36.2) 15.2 (11.6, 19.2)
Plurality
 Single 23.7 (20.6, 27.0) 0.702 11.0 (8.7, 13.5) 0.751
 Multiple 20.0 (4.9, 42.4) 20.0 (4.9, 42.4)
Maternal race/ethnicity
 Non-Hispanic White 22.6 (18.3, 27.3) 0.030 11.3 (8.2, 15.0) 0.092
 Non-Hispanic Black 31.8 (23.4, 40.6) 14.5 (8.7, 21.8)
 Hispanic 21.2 (16.0, 26.9) 9.7 (6.2, 14.1)
 Non-Hispanic Asian/PI 28.6 (11.7, 48.2) 14.3 (3.6, 32.1)
 Other/unknown 27.8 (10.1, 48.9) 16.7 (4.1, 36.5)
Maternal age
 <19 years 28.3 (17.0, 40.7) 0.450 11.3 (4.6, 21.4) 0.439
 20–24 years 19.0 (12.7, 26.3) 9.5 (5.2, 15.4)
 25–29 years 20.8 (14.7, 27.6) 6.0 (3.0, 10.6)
 30–34 years 29.7 (22.7, 37.0) 14.8 (9.8, 20.9)
 ≥35 years 23.8 (18.3, 29.7) 14.3 (10.0, 19.4)
Geographic area
 Metropolitan 24.6 (21.3, 28.1) 0.088 11.8 (9.4, 14.5) 0.046
 Non-Metropolitan 15.3 (8.1, 24.5) 5.6 (1.8, 12.5)
State
 Arizona 14.7 (7.5, 24.1) 0.132 4.4 (1.2, 11.2) 0.076
 Colorado 26.9 (15.8, 39.3) 13.5 (5.9, 24.1)
 Georgia 37.5 (21.3, 53.7) 21.9 (9.6, 37.2)
 Illinois 19.0 (10.5, 29.5) 9.5 (3.9, 18.2)
 Massachusetts 24.3 (12.1, 38.8) 10.8 (3.4, 23.0)
 North Carolina 26.0 (14.9, 38.6) 8.0 (2.6, 17.5)
 New Jersey 32.0 (19.7, 45.0) 22.0 (11.8, 34.2)
 New York 22.4 (14.2, 31.7) 15.3 (8.6, 23.7)
 Texas 23.8 (18.8, 29.2) 9.8 (6.5, 13.8)
Presence of heart defectsc
 With heart defects 18.8 (12.3, 26.3) 0.773 9.4 (5.0, 15.5) 0.741
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Characteristica
1-month survival probability 
(95%CI)
P-valueb for 
difference in 1-
month survival
1-year survival probability 
(95%CI)
P-valueb for 
difference in 1-
year survival
 No heart defects 25.0 (21.5, 28.6) 12.0 (9.5, 14.8)
Presence of omphalocele
 With omphalocele 19.2 (9.9, 30.9) 0.198 9.6 (3.5, 19.4) 0.246
 No omphalocele 24.3 (21.1, 27.7) 11.7 (9.4, 14.3)
Birth period
 1999–2002 25.8 (20.6, 31.1) 0.292 11.4 (7.9, 15.5) 0.477
 2003–2007 22.8 (19.0, 26.9) 11.7 (8.8, 14.9)
Total 24.0 (20.8, 27.2) 11.5 (9.3, 14.1)
aUnknown was excluded except as indicated.
bP-values based on log-rank test.
c
Heart defects include common truncus, transposition of great arteries, tetralogy of Fallot, atrioventricular septal defect, aortic valve stenosis, 
hypoplastic left heart syndrome, and coarctation of aorta.
CI, confidence interval; PI, Pacific Islander.
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TABLE V
One-Month and 1-Year Survival Probabilities (Expressed as Percentage) for Trisomy 18 in Nine US states, 
1999–2007 Birth Cohort
Characteristica
1-month survival probability 
(95%CI)
P-valueb for 
difference in 1-
month survival
1-year survival probability 
(95%CI)
P-valueb for 
difference in 1-
year survival
Infant sex
 Male 24.6 (20.6, 28.8) <0.001 10.8 (8.1, 13.9) <0.001
 Female 42.9 (39.1, 46.6) 14.4 (11.9, 17.1)
Gestational age
 <32 weeks 11.7 (7.7, 16.5) <0.001 4.9 (2.5, 8.4) <0.001
 32–36 weeks 26.4 (21.3, 31.6) 9.4 (6.3, 13.2)
 ≥37 weeks 48.8 (44.7, 52.7) 17.2 (14.3, 20.3)
Plurality
 Single 36.5 (33.6, 39.4) 0.036 13.2 (11.3, 15.4) 0.077
 Multiple 19.5 (9.2, 32.7) 7.3 (1.9, 17.8)
Maternal race/ethnicity
 Non-Hispanic White 33.1 (28.9, 37.4) 0.002 13.6 (10.7, 16.9) 0.017
 Non-Hispanic Black 44.7 (37.9, 51.3) 17.3 (12.5, 22.7)
 Hispanic 35.8 (30.9, 40.7) 10.1 (7.3, 13.5)
 Non-Hispanic Asian/PI 23.7 (11.8, 37.9) 13.2 (4.8, 25.8)
 Other/unknown 43.3 (25.6, 59.9) 23.3 (10.3, 39.4)
Maternal age
 <19 years 46.3 (34.1, 57.6) 0.419 10.4 (4.6, 19.1) 0.924
 20–24 years 31.4 (24.3, 38.8) 14.7 (9.7, 20.8)
 25–29 years 34.1 (27.2, 41.0) 12.3 (8.0, 17.6)
 30–34 years 34.5 (28.0, 41.1) 12.0 (8.0, 16.9)
 ≥35 years 37.6 (33.4, 41.8) 14.3 (11.4, 17.5)
Geographic area
 Metropolitan 37.0 (34.0, 40.0) 0.008 13.4 (11.4, 15.6) 0.028
 Non-metropolitan 25.6 (18.1, 33.8) 9.4 (5.0, 15.5)
State
 Arizona 22.0 (15.1, 29.9) <0.001 9.3 (4.9, 15.4) 0.002
 Colorado 30.5 (19.4, 42.4) 20.3 (11.2, 31.4)
 Georgia 49.2 (36.2, 60.9) 24.6 (14.7, 35.9)
 Illinois 26.8 (19.4, 34.7) 10.2 (5.7, 16.2)
 Massachusetts 55.1 (40.2, 67.7) 22.4 (12.0, 34.8)
 North Carolina 42.4 (32.2, 52.2) 9.8 (4.8, 16.9)
 New Jersey 42.1 (30.9, 52.8) 14.5 (7.7, 23.3)
 New York 43.3 (34.6, 51.7) 18.9 (12.6, 26.1)
 Texas 34.9 (30.3, 39.6) 10.6 (7.9, 13.9)
Presence of heart defectsc
 With heart defects 33.2 (26.6, 39.8) 0.866 5.7 (3.0, 9.6) 0.114
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Characteristica
1-month survival probability 
(95%CI)
P-valueb for 
difference in 1-
month survival
1-year survival probability 
(95%CI)
P-valueb for 
difference in 1-
year survival
 No heart defects 36.7 (33.6, 39.9) 15.0 (12.8, 17.4)
Presence of omphalocele
 With omphalocele 24.1 (14.1, 35.7) 0.002 5.2 (1.4, 13.0) 0.001
 No omphalocele 36.8 (33.9, 39.7) 13.8 (11.8, 16.0)
Birth period
 1999–2002 37.8 (33.0, 42.5) 0.318 14.0 (10.8, 17.6) 0.397
 2003–2007 35.2 (31.7, 38.7) 13.0 (10.7, 15.6)
Total 36.1 (33.3, 38.9) 13.4 (11.5, 15.5)
aUnknown was excluded except as indicated.
bP-values based on log-rank test.
c
Heart defects include common truncus, transposition of great arteries, tetralogy of Fallot, atrioventricular septal defect, aortic valve stenosis, 
hypoplastic left heart syndrome, and coarctation of aorta.
CI, confidence interval; PI, Pacific Islander.
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TABLE VI
Adjusted Hazard Ratios (aHR) and 95% Confidence Intervals (CI) for 1-Year and 5-Year Survival for Children 
With Trisomy 13 and Trisomy 18 From Nine US States, 1999–2007 Birth Cohort
Characteristic
Trisomy 13 Trisomy 18
1-year survival aHR 
(95%CI)
5-year survivala aHR 
(95%CI)
1-year survival aHR 
(95%CI)
5-year survivala aHR 
(95%CI)
Infant sex
 Male 1.0 1.0 1.0 1.0
 Female 0.8 (0.7, 1.0) 0.8 (0.7, 1.0) 0.7 (0.6, 0.8) 0.7 (0.6, 0.9)
Gestational age
 <32 weeks 1.9 (1.6, 2.4) 1.9 (1.5, 2.5) 2.6 (2.2, 3.1) 2.7 (2.2, 3.4)
 32–36 weeks 1.4 (1.2, 1.7) 1.3 (1.0, 1.6) 1.5 (1.3, 1.8) 1.5 (1.2, 1.8)
 ≥37 weeks 1.0 1.0 1.0 1.0
Plurality
 Single Excluded from model 1.1 (0.8, 1.6) 0.9 (0.6, 1.4)
 Multiple 1.0 1.0
Maternal race/ethnicity
 Non-Hispanic White 1.0 1.0 1.0 1.0
 Non-Hispanic Black 0.8 (0.6, 1.0) 0.7 (0.5, 1.0) 0.8 (0.7, 1.0) 0.7 (0.6, 0.9)
 Hispanic 1.0 (0.8, 1.2) 1.0 (0.8, 1.2) 1.0 (0.9, 1.2) 0.9 (0.8, 1.1)
 Non-Hispanic Asian/PI 0.7 (0.4, 1.2) 0.8 (0.5, 1.5) 1.0 (0.7, 1.4) 0.8 (0.5, 1.2)
 Other/unknown 1.4 (0.8, 2.5) 1.4 (0.7, 2.7) 1.1 (0.7, 1.7) 1.0 (0.6, 1.7)
Geographic area
 Metropolitan 1.0 1.0 1.0 1.0
 Non-Metropolitan 1.2 (0.9, 1.5) 1.3 (0.9, 1.8) 1.1 (0.9, 1.4) 1.1 (0.8, 1.4)
State
 Arizona 1.3 (1.0, 1.8) 1.4 (1.0, 1.9) 1.2 (0.9, 1.5) 1.0 (0.8, 1.3)
 Colorado 1.0 (0.7, 1.4) 1.1 (0.7, 1.6) 1.0 (0.8, 1.4) 1.1 (0.8, 1.6)
 Georgia 0.7 (0.5, 1.1) 0.8 (0.5, 1.3) 0.7 (0.5, 1.0) 0.9 (0.6, 1.3)
 Illinoisb 1.1 (0.8, 1.5) – 1.2 (1.0, 1.5) –
 Massachusetts 1.2 (0.8, 1.7) 1.7 (1.1, 2.6) 0.8 (0.6, 1.1) 0.9 (0.6, 1.3)
 North Carolina 1.0 (0.7, 1.3) 1.0 (0.6, 1.5) 1.0 (0.8, 1.3) 0.9 (0.6, 1.2)
 New Jersey 0.9 (0.6, 1.2) 1.0 (0.7, 1.4) 0.9 (0.7, 1.2) 1.0 (0.7, 1.3)
 New York 1.0 (0.7, 1.3) 1.2 (0.9, 1.6) 0.8 (0.6, 1.0) 0.7 (0.6, 1.0)
 Texas 1.0 1.0 1.0 1.0
Heart defectsc
 With heart defects Excluded from model 1.2 (1.0, 1.4) 1.3 (1.1, 1.6)
 No heart defects 1.0 1.0
Omphalocele
 With omphalocele Excluded from model 1.5 (1.1, 1.9) 1.6 (1.1, 2.3)
 No omphalocele 1.0 1.0
a
Based on children born 1999–2005; excludes Illinois, which provided mortality data only up to 1 year of age.
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b
Illinois provided mortality data up to age 1 only.
c
Heart defects include common truncus, transposition of great arteries, tetralogy of Fallot, atrioventricular septal defect, aortic valve stenosis, 
hypoplastic left heart syndrome, and coarctation of aorta.
PI, Pacific Islander.
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